MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Phase III Trial
MedXY News
EnglishTag

Phase III Trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update
DermatologymelanomaDaromun

Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update

By MedXY|Aug 13, 2026

Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial
newsAsparaginase
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Pancreatic Cancer

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial

By MedXY|Dec 8, 2025

In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial
Clinical Updateschemoradiotherapyhead and neck cancer

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY|Sep 8, 2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cel

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models